Attending UKONS Annual Conference 2023? We would be delighted to meet you at Stand 35 and answer any questions you may have about the Oncotype DX® Test, the genomic assay supporting adjuvant chemotherapy treatment decision-making for patients with HR+, HER2–, invasive early-stage breast cancer.
Every cancer is unique and affects each diagnosed person differently based on the individual biology of his or her disease. To address this diversity and make cancer care smarter at every stage, our Oncotype DX genomic tests and services portfolio delivers clinically relevant genomic intelligence that reveals the individual biology of a patient's tumour. This additional genomic insight helps clinicians optimise treatment decisions for breast, colon, and prostate cancers by answering questions such as:
- Do I need chemotherapy?
- Do I have an aggressive form of cancer?
- Do I need surgery?
- Will I need additional treatment after surgery?
The Oncotype DX tests have been used to guide treatment decisions for more than 1 million cancer patients worldwide.
"With millions of cancer patients around the world, it is critical to be able to individualise care. Oncotype DX tests have paved the way for precision medicine by providing personalised information based on the unique biology of every cancer, and by enabling confident, individualised treatment decisions. Genomic testing has become a mainstream component of cancer care, and patients are seeing the benefits through improved outcomes."